Glycated albumin is the preferred marker for assessing glycaemic control in advanced chronic kidney disease

NDT Plus

Volumn 4, Issue 6, 2011, Pages 368-375

  Vos, Frederiek E ^a   Schollum, John B ^a   Walker, Robert J ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Chronic kidney disease; Fructosamine; Glycaemic control; Glycated albumin; Glycated haemoglobin

Indexed keywords

FRUCTOSAMINE; GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C;

CHRONIC KIDNEY DISEASE; DIABETES EDUCATION; DIABETES MELLITUS; ERYTHROCYTE LIFESPAN; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; SURVIVAL;

EID: 84856332978     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfr140     Document Type: Review

References (85)

1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-787 (Pubitemid 34000780)
2. Collins AJ, Foley R, Herzog C et al. Excerpts from the United States Renal Data System 2010 annual data report: atlas of end-stage renal disease in the United States. Am J Kidney Dis 2011; 57 (1 Suppl 1): A1-A8, e1-e526
3. Valderrabano F, Berthoux FC, Jones EH et al. Report on management of renal failure in Europe, XXV, 1994 end stage renal disease and dialysis report. Nephrol Dial Transplant 1996; 11 (Suppl 1): 2-21
4. Gaede P, Lund-Andersen H, Parving HH et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591 (Pubitemid 351214285)
5. Rayner HC, Pisoni RL, Bommer J et al. Mortality and hospitalization in haemodialysis patients in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004; 19: 108-120 (Pubitemid 38072622)
6. Adler AI, Stevens RJ, Manley SE et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-232 (Pubitemid 35463925)
7. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the diabetes control and complications trial research group. N Engl J Med 1993; 329: 977-986
8. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 836-853
9. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117
10. Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572 (Pubitemid 351831357)
11. Wainai H, Katsukawa F, Takei I et al. Influence of glycemic control and hypertension onurinarymicroprotein excretionin non-insulin-dependent diabetes mellitus. J Diabet Complications 1991; 5: 160-161
12. Kawazu S, Tomono S, Shimizu M et al. The relationship between early diabetic nephropathy and control of plasma glucose in noninsulin-dependent diabetes mellitus. The effect of glycemic control on the development and progression of diabetic nephropathy in an 8-year follow-up study. J Diabet Complications 1994; 8: 13-17 (Pubitemid 24371436)
13. Hovind P, Rossing P, Tarnow L et al. Progression of diabetic nephropathy. Kidney Int 2001; 59: 702-709 (Pubitemid 32157935)
14. Rossing K, Christensen PK, Hovind P et al. Progression of nephropathy in type 2 diabetic patients. Kidney Int 2004; 66: 1596-1605 (Pubitemid 39298395)
15. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensinconverting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462 (Pubitemid 23335891)
16. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559 (Pubitemid 351831356)
17. Okada T, Nakao T, Matsumoto H et al. Association between markers of glycemic control, cardiovascular complications and survival in type 2 diabetic patients with end-stage renal disease. Intern Med 2007; 46: 807-814 (Pubitemid 47261661)
18. Oomichi T, Emoto M, Tabata T et al. Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7-year observational study. Diabetes Care 2006; 29: 1496-1500 (Pubitemid 44127570)
19. Kalantar-Zadeh K, Kopple JD, Regidor DL et al. A1C and survival in maintenance hemodialysis patients. Diabetes Care 2007; 30: 1049-1055 (Pubitemid 46684623)
20. Drechsler C, Krane V, Ritz E et al. Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation 2009; 120: 2421-2428
21. McMurray SD, Johnson G, Davis S et al. Diabetes education and care management significantly improve patient outcomes in the dialysis unit. Am J Kidney Dis 2002; 40: 566-575 (Pubitemid 34971286)
22. Morioka T, Emoto M, Tabata T et al. Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care 2001; 24: 909-913 (Pubitemid 33636068)
23. Freedman BI, Andries L, Shihabi ZK et al. Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients. Clin J Am Soc Nephrol 2011; 6: 1635-1643
24. Shurraw S, Majumdar SR, Thadhani R et al. Glycemic control and the risk of death in 1, 484 patients receiving maintenance hemodialysis. Am J Kidney Dis 2010; 55: 875-884
25. Williams ME, Lacson E Jr, Wang W et al. Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: comparative results of traditional and time-dependent Cox model analyses. Clin J Am Soc Nephrol 2010; 5: 1595-1601
26. National Kidney Foundation. K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007; 49 (2 Suppl 2): S12-S154
27. Mak RH. Impact of end-stage renal disease and dialysis on glycemic control. Semin Dial 2000; 13: 4-8
28. Gerich JE, Meyer C, Woerle HJ et al. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care 2001; 24: 382-391 (Pubitemid 32119142)
29. Abe M, Kikuchi F, Kaizu K et al. The influence of hemodialysis membranes on the plasma insulin level of diabetic patients on maintenance hemodialysis. Clin Nephrol 2008; 69: 354-360 (Pubitemid 351663170)
30. Marshall J, Jennings P, Scott A et al. Glycemic control in diabetic CAPD patients assessed by continuous glucose monitoring system (CGMS). Kidney Int 2003; 64: 1480-1486 (Pubitemid 37153816)
31. Bunn H, Haney D, Kamin S et al. The biosynthesis of human hemoglobin A1c. Slow glycosylation of hemoglobin in vivo. J Clin Invest 1976; 57: 1652-1659
32. Armbruster DA. Fructosamine: structure, analysis, and clinical usefulness. Clin Chem 1987; 33: 2153-2163
33. Garlick R, Mazer J. The principal site of nonenzymatic glycosylation of human serum albumin in vivo. J Biol Chem 1983; 258: 6142-6146 (Pubitemid 13106789)
34. Tahara Y, Shima K. Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care 1995; 18: 440-447
35. Goldstein DE, Little RR, Lorenz RA et al. Tests of glycemia in diabetes. Diabetes Care 2004; 27 (Suppl 1): S91-S93
36. Fitzgibbons JF, Koler RD, Jones RT. Red cell age-related changes of hemoglobins AIa1b and AIc in normal and diabetic subjects. J Clin Invest 1976; 58: 820-824
37. Tahara Y, Shima K. The response of GHb to stepwise plasma glucose change over time in diabetic patients. Diabetes Care 1993; 16: 1313-1314 (Pubitemid 23259881)
38. Rohlfing CL, Wiedmeyer HM, Little RR et al. Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care 2002; 25: 275-278 (Pubitemid 41079621)
39. Borg R, Kuenen JC, Carstensen B et al. HbA(c) and mean blood glucose show stronger associations with cardiovascular disease risk factors than do postprandial glycaemia or glucose variability in persons with diabetes: the A1C-Derived Average Glucose (ADAG) study. Diabetologia 2011; 54: 69-72
40. Inaba M, Okuno S, Kumeda Y et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol 2007; 18: 896-903 (Pubitemid 46434506)
41. Peacock T, Shihabi Z, Bleyer A et al. Comparison of glycated albumin and hemoglobin A1c levels in diabetic subjects on hemodialysis. Kidney Int 2008; 73: 1062-1068 (Pubitemid 351543905)
42. Ng J, Jennings P, Laboi P et al. Erythropoetin treatment significantly alters measured glycated haemoglobin (HbA1c). Diabet Med 2008; 25: 239-240 (Pubitemid 351293401)
43. Ly J, Marticorena R, Donnelly S. Red blood cell survival in chronic renal failure. Am J Kidney Dis 2004; 44: 715-719 (Pubitemid 39237616)
44. Vos FE, Schollum JB, Coulter CV et al. Red blood cell survival in patients on long-term dialysis. Am J Kidney Dis 2011; 58: 591-598
45. Virtue M, Furne J, Nuttall F et al. Relationship between GHb concentration and erythrocyte survival determined from breath carbon monoxide concentration. Diabetes Care 2004; 27: 931-935 (Pubitemid 38420217)
46. Nakao T, Matsumoto H, Okada T et al. Influence of erythropoietin treatment on hemoglobin A1c levels in patients with chronic renal failure on hemodialysis. Intern Med 1998; 37: 826-830
47. Okada T, Nakao T, Yamanaka T et al. Influence of darbepoetin-alpha therapy on HbA(1c) values in hemodialysis patients. Clin Nephrol 2009; 72: 244-246
48. Kim C, Bullard KM, Herman WH et al. Association between iron deficiency and A1C Levels among adults without diabetes in the National Health and Nutrition Examination Survey, 1999-2006. Diabetes Care 2010; 33: 780-785
49. Gram-Hansen P, Eriksen J, Mourits-Andersen T et al. Glycosylated haemoglobin (HbA1c) in iron-and vitamin B12 deficiency. J Intern Med 1990; 227: 133-136 (Pubitemid 20038884)
50. Fluckiger R, Harmon W, MeierWet al. Hemoglobin carbamylation in uremia. N Engl J Med 1981; 304: 823-827
51. Weykamp CW, Penders TJ, Siebelder CW et al. Interference of carbamylated and acetylated hemoglobins in assays of glycohemoglobin by HPLC, electrophoresis, affinity chromatography, and enzyme immunoassay. Clin Chem 1993; 39: 138-142 (Pubitemid 23034974)
52. Paisey R, Banks R, Holton R et al. Glycosylated haemoglobin in uraemia. Diabet Med 1986; 3: 445-448 (Pubitemid 16030507)
53. Makita Z, Vlassara H, Rayfield E et al. Hemoglobin-AGE: a circulating marker of advanced glycosylation. Science 1992; 258: 651-653
54. Johnson RN, Metcalf PA, Baker JR. Fructosamine: a new approach to the estimation of serum glycosylprotein. An index of diabetic control. Clin Chim Acta 1983; 127: 87-95 (Pubitemid 13168108)
55. Dolhofer R, Wieland OH. Increased glycosylation of serum albumin in diabetes mellitus. Diabetes 1980; 29: 417-422 (Pubitemid 11018459)
56. Schleicher ED, Mayer R, Wagner EM et al. Is serum fructosamine assay specific for determination of glycated serum protein? Clin Chem 1988; 34: 320-323 (Pubitemid 18064983)
57. Kunika K, Itakura M, Yamashita K. Correction of fructosamine value for serum albumin and globulin concentrations. Diabetes Res Clin Pract 1991; 13: 37-44
58. Schleicher ED, Olgemoller B, Wiedenmann E et al. Specific glycation of albumin depends on its half-life. Clin Chem 1993; 39: 625-628 (Pubitemid 23118312)
59. Lamb E, Mainwaring-Burton R, Dawnay A. Effect of protein concentration on the formation of glycated albumin and fructosamine. Clin Chem 1991; 37: 2138-2139
60. Staley MJ. Fructosamine and protein concentrations in serum. Clin Chem 1987; 33: 2326-2327
61. Mosca A, Carenini A, Zoppi F et al. Plasma protein glycation as measured by fructosamine assay. Clin Chem 1987; 33: 1141-1146 (Pubitemid 17157903)
62. Takahashi S, Uchino H, Shimizu T et al. Comparison of glycated albumin (GA) and glycated hemoglobin (HbA1c) in type 2 diabetic patients: usefulness of GA for evaluation of short-term changes in glycemic control. Endocr J 2007; 54: 139-144 (Pubitemid 46481682)
63. Pu LJ, Lu L, Shen WF et al. Increased serum glycated albumin level is associated with the presence and severity of coronary artery disease in type 2 diabetic patients. Circ J 2007; 71: 1067-1073 (Pubitemid 46998021)
64. Amore A, Cirina P, Conti G et al. Amadori-configurated albumin induces nitric oxide-dependent apoptosis of endothelial cells: a possible mechanism of diabetic vasculopathy. Nephrol Dial Transplant 2004; 19: 53-60 (Pubitemid 38072615)
65. Bilo HJ, Struijk DG, Boeschoten EW et al. A comparison of three methods to assess metabolic control in diabetic patients on CAPD treatment. Neth J Med 1988; 33: 217-224
66. Nunoi K, Kodama T, Sato Y et al. Comparison of reliability of plasma fructosamine and glycosylated hemoglobin assays for assessing glycemic control in diabetic patients on hemodialysis. Metabolism 1991; 40: 986-989
67. Ichikawa H, Nagake Y, Takahashi M et al. What is the best index of glycemic control in patients with diabetes mellitus on hemodialysis? Nihon Jinzo Gakkai Shi 1996; 38: 305-308 (Pubitemid 126496398)
68. Morgan L, Marenah CB, Jeffcoate WJ et al. Glycated proteins as indices of glycaemic control in diabetic patients with chronic renal failure. Diabet Med 1996; 13: 514-519 (Pubitemid 26201502)
69. Joy MS, Cefalu WT, Hogan SL et al. Long-term glycemic control measurements in diabetic patients receiving hemodialysis. Am J Kidney Dis 2002; 39: 297-307 (Pubitemid 34174252)
70. Chujo K, Shima K, Tada H et al. Indicators for blood glucose control in diabetics with end-stage chronic renal disease: GHb vs. glycated albumin (GA). J Med Invest 2006; 53: 223-228 (Pubitemid 44619840)
71. Nagayama H, Inaba M, Okabe R et al. Glycated albumin as an improved indicator of glycemic control in hemodialysis patients with type 2 diabetes based on fasting plasma glucose and oral glucose tolerance test. Biomed Pharmacother 2009; 63: 236-240
72. Riveline JP, Teynie J, Belmouaz S et al. Glycaemic control in type 2 diabetic patients on chronic haemodialysis: use of a continuous glucose monitoring system. Nephrol Dial Transplant 2009; 24: 2866-2871
73. Chen HS, Wu TE, Lin HD et al. Hemoglobin A(1c) and fructosamine for assessing glycemic control in diabetic patients with CKD stages 3 and 4. Am J Kidney Dis 2010; 55: 867-874
74. Vos FE, Schollum JB, Coulter CV et al. Assessment of markers of glycaemic control in diabetic patients with chronic kidney disease using continuous glucose monitoring. Nephrology 2011; doi: 10.1111/j.1440-1797.2011.01517.x.
75. Freedman BI, Shihabi ZK, Andries L et al. Relationship between assays of glycemia in diabetic subjects with advanced chronic kidney disease. Am J Nephrol 2010; 31: 375-379
76. Freedman BI, Shenoy RN, Planer JA et al. Comparison of glycated albumin and hemoglobin A1c concentrations in diabetic subjects on peritoneal and hemodialysis. Perit Dial Int 2010; 30: 72-79
77. Kazempour-Ardebili S, Lecamwasam VL, Dassanyake T et al. Assessing glycemic control in maintenance hemodialysis patients with type 2 diabetes. Diabetes Care 2009; 32: 1137-1142
78. Chico A, Vidal-Rios P, Subira M et al. The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. Diabetes Care 2003; 26: 1153-1157 (Pubitemid 36929264)
79. Nathan DM, Turgeon H, Regan S. Relationship between glycated haemoglobin levels and mean glucose levels over time. Diabetologia 2007; 50: 2239-2244 (Pubitemid 47512407)
80. Ikizler TA, Pupim LB, Brouillette JR et al. Hemodialysis stimulates muscle and whole body protein loss and alters substrate oxidation. Am J Physiol Endocrinol Metab 2002; 282: E107-E116 (Pubitemid 34654113)
81. Cooper S, Iliescu EA, Morton AR. The relationship between dialysate protein loss and membrane transport status in peritoneal dialysis patients. Adv Perit Dial 2001; 17: 244-247
82. Okada T, Nakao T, Matsumoto H et al. Influence of proteinuria on glycated albumin values in diabetic patients with chronic kidney disease. Intern Med 2011; 50: 23-29
83. Don BR, Kaysen G. Serum albumin: relationship to inflammation and nutrition. Semin Dial 2004; 17: 432-437 (Pubitemid 40110428)
84. Chadban SJ, Briganti EM, Kerr PG et al. Prevalence of kidney damage in Australian adults: the AusDiab kidney study. J Am Soc Nephrol 2003; 14 (7 Suppl 2): S131-S138 (Pubitemid 36750508)
85. Fukuoka K, Nakao K, Morimoto H et al. Glycated albumin levels predict long-term survival in diabetic patients undergoing haemodialysis. Nephrology 2008; 13: 278-283 (Pubitemid 351668328)